Skip to content

Effect of different doses of magnesium sulfate combined with Ropivacaine femoral nerve block on tourniquet related hypertension in patients undergoing lower extremity surgery

Effect of different doses of magnesium sulfate combined with Ropivacaine femoral nerve block on tourniquet related hypertension in patients undergoing lower extremity surgery

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300077081
Enrollment
Unknown
Registered
2023-10-27
Start date
2023-11-10
Completion date
Unknown
Last updated
2023-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

osteoarthritis

Interventions

Group R:0.375% ropivacaine 15ml femoral nerve block was performed
Group RM1:0.375% ropivacaine +250mg magnesium sulfate 15ml femoral nerve block was performed
Group RM2:0.375% ropivacaine +500mg magnesium sulfate 15ml femoral nerve block was performed
Group RM3:0.375% ropivacaine +1000mg magnesium sulfate 15ml femoral nerve block was performed

Sponsors

Affiliated Hospital of Xuzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Adult patients (18-75 years old); ASA rating ?-?; Unilateral total knee arthroplasty under elective general anesthesia is planned, and pneumatic tourniquet is required during the operation. Signed informed consent and did not participate in other clinical trials at the same time

Exclusion criteria

Exclusion criteria: Patients taking anti-NMDA neurodrugs, opioids, or psychotropic drugs before surgery; Patients are allergic to magnesium sulfate or other drugs used in this study; History of hepatic encephalopathy or end-stage hepatic encephalopathy (Child-Pugh grade B or C); GFR 1.5h; Patients with local skin infection or coagulation dysfunction at the block site; Those who were unable to perform the numerical Pain Score (NRS) or the questionnaire used in this study; Patients with heavy bleeding during the operation (blood loss =800ml); Voluntary withdrawal; Postoperative admission to ICU; Follow-up of this subject failed.Patients taking anti-NMDA neurodrugs, opioids, or psychotropic drugs before surgery;

Design outcomes

Primary

MeasureTime frame
Incidence of tourniquet associated hypertension;

Secondary

MeasureTime frame
systolic blood pressure;Systolic blood pressure;Systolic blood pressure;Systolic blood pressure;Diastolic blood pressure;Diastolic blood pressure;Diastolic blood pressure;Diastolic blood pressure;Mean arterial pressure;Mean arterial pressure;Mean arterial pressure;Mean arterial pressure;Heart rate;Heart rate;Heart rate;Heart rate;Total morphine equivalent consumption;static NRS scores;Time of first PCA after operation;Times of pressing analgesic pump;Remedial analgesia;Time of first getting out of bed after operation;Operation duration;Tourniquet use time;Duration of anesthesia;Intraoperative Propofol dosage;Intraoperative Remifentanil dosage;Intraoperative dose of deoxyadrenaline;Intraoperative atropine dosage;Intraoperative ephedrine dosage;Intraoperative urapidil dosage;Intraoperative blood loss;Intraoperative infusion volume;First time out of bed after surgery;Postoperative hospital stay;Dynamic NRS scoring;Onset time of sensory block;Onset time of pain block;Onset time of motor block;Duration of sensory block;Duration of pain block;Duration of motor block;Magnesium levels in the blood;Recovery Quality Score (QoR-15);Postoperative adverse reaction;

Countries

China

Contacts

Public ContactYan Ming

Affiliated Hospital of Xuzhou Medical University

yiy3001@163.com+86 180 5226 8329

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026